Orphan Drug Designation for first-in-class autotaxin cancer therapy
Drug Discovery World
MARCH 11, 2024
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted Orphan Drug Status, conferring certain benefits during development and commercialisation.
Let's personalize your content